REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 P&L / Income Statement

REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

4,290,700,000 US dollars

Cost of revenue (calculated)

576,500,000 US dollars

Gross profit (calculated)

3,714,200,000 US dollars

Operating expenses (calculated)

2,420,700,000 US dollars

Income from operations

1,293,500,000 US dollars

Total other income (expense)

234,300,000 US dollars

Income before income taxes

1,527,800,000 US dollars

Income tax expense

230,900,000 US dollars

Net income

1,296,900,000 US dollars

Lynozyfic

16,500,000 US dollars

Other products

0 US dollars

EYLEA HD And EYLEA - UNITED STATES

1,008,500,000 US dollars

EYLEA HD - UNITED STATES

596,300,000 US dollars

Evkeeza - UNITED STATES

53,300,000 US dollars

EYLEA Net Product Sales - UNITED STATES

412,200,000 US dollars

Libtayo - UNITED STATES

342,600,000 US dollars

Libtayo - Rest Of World

146,800,000 US dollars

Praluent - UNITED STATES

74,700,000 US dollars

Undisclosed (calculated)

1,639,800,000 US dollars

Cost of goods sold, collaboration and contract manufacturing

576,500,000 US dollars

Research and development

1,631,600,000 US dollars

Acquired in-process research and development

127,000,000 US dollars

Selling, general, and administrative

662,100,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.